English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

According to the sources, vaginal candidiasis develops on the background of papillomavirus infection in 36–41% of cases. The violation of the vaginal bioceno sis decreases the immunological potential of the epithelium, and creates favourable conditions for the carcinogenic effect of the human papillomavirus. We have examined 100 patients (18–40 years old) in order to evaluate the efficiency and safeness of Fluzamed (active ingredient: Fluconazole 150 mg) usage in treatment of vulvovaginal candidiasis with cervical dysplasia caused by papillomavirus infection. The treatment control was performed three times: after the first course of treatment, in 3 and 6 months. The study has shown that due to Fluconazole 150 mg treatment, the disease recurrences at 3 and 6 months were occurred significantly rarely as compared to the cases of Butoconazole 20 mg/g application. The complete eradication of PVI was clinically and laboratory con firmed after 3 and 6 months of treatment. In our study, we have confirmed the safety of a systemic drug Fluzamed (active ingredient: Fluconazole 150 mg) usage by the lack of adverse reactions after its administration.

Efficiency of using antifungal drugs in women with vaginal candidiasis on the background of papillomavirus infection